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Abstract
Kratom, derived from the plant Mitragyna speciosa, is reported to produce stimulant-like effects
at low doses and opiate-like effects at high doses. Mitragynine (MG) and 7-hydroxymitragynine
(7-HMG) are the major psychoactive constituents of kratom, but the neural mechanisms of these
alkaloids are not clear. Given that the effects of kratom are often compared to those of drugs with
a high abuse liability, the current study aimed to determine the effect of MG and 7-HMG on
reward-related neurotransmission. In vivo fixed potential amperometry was used to quantify
stimulation-evoked phasic dopamine release in the nucleus accumbens (NAc) of anesthetized
male and female mice. During dopamine recordings, mice received an i.p. injection of either MG
(1, 15, or 30 mg/kg i.p.), 7-HMG (0.5, 1, or 2 mg/kg i.p.), or vehicle, and dopamine recordings
continued for 90 min. Using specific stimulation parameters, dopamine autoreceptor functioning
was measured 30 min post injection. Sex effects were observed following MG but not 7-HMG.
In males, there was a significant time x MG dose interaction with the low dose seeming to
increase dopamine release relative to vehicle and the higher doses towards the end of the
recording period. However, follow-up tests revealed no significant dopamine release differences
between doses at specific time points. Low dose MG also increased dopamine autoreceptor
functioning (+50% from vehicle) in males. Regarding 7-HMG, both sexes responded similarly
with a significant time x 7-HMG dose interaction effect on dopamine release. Follow-up tests
revealed significant differences between 7-HMG doses from 60-90 min post injection, with the
low dose increasing dopamine release (+18% from vehicle) compared to the high dose (-22%
from vehicle). 7-HMG did not alter dopamine autoreceptor functioning. Neither MG nor 7-HMG
altered the clearance rate of stimulation-evoked dopamine, indicating no drug effect on
dopamine transporter functioning. In conclusion, dose effects were observed following both MG
and 7-HMG. The low dose of MG (1 mg/kg) affected dopamine release in males more than
females, potentially through actions on dopamine autoreceptors, and in both sexes the low dose
of 7-HMG (0.5 mg/kg) increased dopamine release while the high dose (2 mg/kg) had the
opposite effect. Although these increases in dopamine release are considerably less than those
normally observed in stimulants with a high abuse liability, these findings do suggest that MG
and 7-HMG alter dopamine transmission. An increased understanding of the neural mechanisms
of kratom may provide insight on its potential uses and abuse liability.
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Examining the Effects of Kratom Alkaloids on Mesolimbic Dopamine Release

Background and History of Kratom
Kratom (Mitragyna speciosa) is a plant native to Southeast Asia that has been consumed
by indigenous cultures for hundreds of years for its complex stimulant, analgesic, and medicinal
effects in the form of capsules or tea-like brews (Ahmad et al. 2012). Within the last decade, the
awareness and availability of kratom has shown a marked increase in the United States (Anwar
and Law, 2016). The American Kratom Association is currently one of the few sources that have
population estimations available. Based on these estimations from the AKA (AKA, 2020), in
2016 the United States imported approximately 4.1 million pounds of kratom material from
Indonesia, one of the world’s largest exporters of kratom. By considering the amount of imported
material that is manufactured into various kratom products and the average consumer
use/dosage, in 2016 there were an estimated 5.1 million kratom consumers in the United States
(AKA, 2020). In 2020, these numbers were greatly increased with approximately 10.2 million
pounds of kratom material imported to the United States and an estimated 12.9 million kratom
consumers. However, when accounting for the volume of direct sales from Indonesian farmers to
U.S. consumers and small vendors, the estimated number of current kratom consumers is even
higher, at 15 million consumers (AKA, 2020). Other researchers have estimated there to be 1016 million people in the United States that use kratom for diverse health reasons (Henningfield,
2019). Furthermore, by using the IMPLAN model based on employment data from the U.S.
Bureau of Economic Analysis, in 2020 the kratom sector accounted for 18,560 jobs, $882,800,00
in labor income, and contributed a total of $1,368,576,000 to the U.S. GDP (AKA, 2020), thus,
signifying the extent of the kratom consumer market and its establishment in the United States.
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Although, the data is not yet clear if these reported numbers were derived exclusively from
kratom sales or were influenced by the presence of integrated business models. The amount of
scientific literature surrounding kratom is expanding but not yet at a rate that mirrors the rise of
its consumption, and many of kratom’s neural mechanisms are still not fully understood.
Specifically, the effect kratom has on neural pathways related to reward processing has not yet
been sufficiently explored.
Historically, the plant has a tumultuous past regarding regulation and legality. Most
notably, the Thai government passed the Kratom Act 2486, effective August 3, 1943, which
made planting the tree illegal. This was in response to a rise in kratom use when opium became
very expensive in Thailand (which the government was profiting from in the form of sanctioned
opium dens with inflated prices) and the Thai government was attempting to gain control of the
opium market (Meireles, 2019). Locals were most commonly using kratom to wean themselves
off their opium dependence and as a stimulant to help manage the painful demands of physical
labor (Veltri and Grundmann, 2019). In 2018, the Thai government legalized the production,
import, export, possession and use of kratom products for medicinal purposes. The distribution
of kratom has consequently grown. Regarding the US, there are currently 6 states that have
labelled kratom as a controlled substance (Alabama, Arkansas, Indiana, Rhode Island, Vermont,
and Wisconsin) (Veltri and Grundmann, 2019). In 2014, synthetic kratom was labelled illegal in
TN, but according to the current legislation, kratom powder, kratom capsules containing pure
kratom powder, and kratom extracts are legal in TN for those over the age of 21 (Williams and
Nikitin, 2020). In 2017, the US Drug Enforcement Administration identified kratom as a Drug of
Concern but received substantial pushback from the kratom user community who touted its
benefits (DEA, 2017). As such, kratom is currently legal in most states and is distributed and/or
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purchased at smoke shops, convenience stores, or online in the form of powder, capsules,
extracts, or is consumed in a tea-like brew (Swogger et al., 2015).

Use of Kratom
“Kratom” is typically consumed as a tea-like brew, commercially prepared liquid, or in
the form of capsules (Henningfield et al., 2017). Mitragyna speciose is a member of the
Rubiaceae family, which also includes the genus Coffea (Eisenman, 2015). Similar to coffee,
kratom has been traditionally used in regions of Southeast Asia as a stimulant to combat fatigue
and improve work productivity, but also to manage pain and opioid withdrawal (Suwanlert,
1975). In addition, kratom preparations have also been used for centuries during socioreligious
ceremonies and to treat various medical conditions such as diarrhea, pain, coughing, or to
ameliorate withdrawal symptoms from other addictive drugs (Ahmad et al. 2012)
(Assanangkornchai, 2007). Inversely in the early 2000s, a cocktail consisting of boiled kratom
leaves, cola soft drink, codeine cough syrup, and ice (or another 4th ingredient) known as
“4x100” became a popular drink and rising social problem among the youth in Thailand
(Davidson et al., 2020). Kratom is most commonly used without a prescription across cultures to
help wean opioid dependence, relieve pain, stimulant purposes, and in some cases recreation
(Boyer et al., 2008) (Davidson et al., 2020). In a 2017 U.S. study detailing kratom user
demographics and use patterns, Garcia-Romeu et al. (2020) found that 91% of their 2,798
respondents in a cross-sectional, anonymous online survey used kratom for pain relief. The
researchers also found most respondents used kratom to help treat mood-related issues like
anxiety (67.2%) or depression (64.5%) and to treat opioid withdrawal symptoms (87.3%)
(Garcia-Romeu et al., 2020). Most of these respondents reported using kratom within the past
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day (80.7%), more than 100 times in total (76.2%), and continued daily use (59.1%) (GarciaRomeu et al., 2020).

Neuropharmacology of Kratom
The neural mechanisms of kratom are not yet understood. Containing more than 3 dozen
indole alkaloids, the psychostimulant and opiate-like effects of kratom are in part attributed to its
two primary alkaloids mitragynine (MG) and its metabolite 7-hydroxymitragynine (7-HMG) that
are exclusive to Mitragyna speciosa (Johnson et al., 2020). MG is an indole-based partial agonist
of the mu-opioid receptor and the most abundant (accounting for up to 66% of the alkaloid
content) psychoactive alkaloid in the plant Mitragyna speciose (Matsumoto et al., 1996). 7HMG, a major metabolite of MG, while present in the plant in much smaller quantities (2% of
the alkaloid content), is noted in numerous studies to be a much more potent opioid agonist and
analgesic (Harun et al., 2015; Matsumoto et. al., 2004; Ponglux et al.,1994). While both MG and
7-HMG both target opioid receptors they differ in their binding affinities (Prozialeck et al.,
2012). In comparative studies, MG has been shown to have less affinity for opioid receptors than
morphine, but 7-HMG has been shown to be approximately 46 times more potent than MG and
13 times more potent than morphine (Matsumoto et al., 2006). Currently, the exact mechanisms
in which kratom alkaloids act at each of the receptors are still being discovered (Matsumoto et.
al., 2004). Kruegel et. al. (2016) reported that MG and 7-HMG seem to have negligible effects
on κ-receptors, although they can act as partial agonists at µ-receptors and competitive
antagonists δ-receptors. While the physiological significance and precise interactions of kratom’s
alkaloids are still largely unclear, they have been shown to bear at least partial affinity for 5HT2C and 5-HT7 serotonin receptors, D2 dopamine receptors, and A2A adenosine receptors

4

(Matsumoto et. al., 2005). Notably, because the alkaloids in kratom produce similar but
nonidentical effects that are distinct from other opioids both structurally and
pharmacodynamically, these compounds have been called “nature’s first” atypical opioids to
properly distinguish them from traditional opioids. (Raffa, Pergolizzi, Taylor, and Ossipov,
2018). Furthermore, while the understanding of kratom’s unique pharmacology is still
developing, it has been postulated that MG is converted to 7-HMG in the liver via hepatic
metabolism (Yusof et. al., 2019). Moreover, there is also emerging evidence suggesting that 7HMG is stable in plasma using rodent and primate models but is subsequently converted to
mitragynine pseudoindoxyl (an even more potent opioid) in human plasma (Kamble et al., 2020).
Consequently, this has led some groups to hypothesize that 7-HMG represents the active
metabolite of MG and 7-HMG accounts for the effects that have historically been attributed to its
precursor MG (Kruegel et. al., 2019; Yusof et. al., 2019). These studies also posit this
endogenous generation of 7-HMG from MG results in any ingested amount of 7-HMG present in
kratom products to be relatively inconsequential (Kruegel et. al., 2019; Yusof et. al., 2019). The
relevance of this discovery has not yet been confirmed in human physiology as current studies
are still utilizing animal models.

Abuse Liability of Kratom
Given the rise in consumption and the neuropharmacological overlap with opioids,
researchers have begun to investigate the potential abuse liability of kratom. To date, there is a
lack of controlled studies and characterization of kratom’s abuse liability in humans (GarciaRomeu et al., 2020). Regarding the available clinical findings, there are some related case reports
suggesting kratom use may lead to withdrawal symptoms (irritability, dysphoria, nausea,
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hypertension, insomnia, yawning, rhinorrhea, myalgia, diarrhea, and arthralgias) (Prozialeck et
al., 2012; Suwanlert, 1975; Trakulsrichai et al., 2013), overdose (Kronstrand et al., 2011), and
the development of tolerance and/or increased intake over time (Hassan et al., 2013). It should be
noted that in many case reports, especially those resulting in death, the negative effects of kratom
are often correlated with compounding substance abuse and mental illness (Swogger et al.,
2018), meaning that clinical kratom withdrawal symptoms are difficult to separate from users’
opioid or other substance withdrawals (Assanangkornchai et al., 2007; Suwanlert, 1975). In a
CDC report from July 2017-December 2017 of 27,338 overdose deaths, 152(<1%) decedents
tested positive for “kratom-involved” on postmortem toxicology (Olsen et al., 2019). Of these
152, kratom was found to be the only substance in 7 decedents, and the researchers report the
presence of additional substances cannot be ruled out (Olsen et al., 2019). Other drugs associated
with these overdoses were fentanyl and its analogs (65.1%), heroin (32.9%), benzodiazepines
(22.4%), prescription opioids (19.7%), and cocaine (18.4%) (Olsen et al., 2019). Additionally,
while not mentioned in this CDC report, alcohol contributes to approximately 22.1% of overdose
deaths related to prescription opioids (Jones, Paulozzi, and Mack, 2010) and the comparative
contribution of kratom to this crisis is still developing. However, a cross-sectional survey of 293
male regular kratom users (regular user - for at least 6 months) (mean age – 28.9 years old)
conducted in Malaysia found those who used kratom more than 3 times a day were 5.19 times
more likely to report severe kratom dependence (Singh and Muller, 2014). Furthermore, within
this sample of users who abruptly abstained from kratom use researchers found 65% of these
users experienced mild withdrawal symptoms, 35% experienced moderate to severe effects, and
64% of these withdrawal symptoms lasted for 1-3 days (Singh and Muller, 2014). Although, the
authors of this study do not clarify what constitutes mild, moderate, or severe effects, some
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withdrawal symptoms experienced by kratom users were: difficulty sleeping, decreased appetite,
nausea, vomiting, muscle spasms, abdominal pain, sweating, shakiness or tremors, aggression,
and hostility (Singh and Muller, 2014). Body aches, cramps, and severe muscle pain were also
reported by 76% of users who abruptly abstained (Singh and Muller, 2014). Results from the
previously mentioned online survey by Garcia-Romeu et al. (2020) also found 9.5% of their
2,798 respondents reported kratom-related withdrawal symptoms. Despite these findings, based
on the DSM-V symptom checklist, 87.7% of respondents did not meet the criteria necessary for a
kratom-related substance use disorder (Garcia-Romeu et al., 2020).
Animal studies have revealed more specific characteristics of the potential abuse liability
of kratom by examining dose-dependent effects of the kratom alkaloids MG and 7-HMG. Rats
have been shown to respond in a dose-dependent manner when assessing locomotor and rewardrelated behaviors after acute MG administration (Yusoff et. al., 2016). In this rodent study,
researchers found that varying doses of MG (1, 10, and 30 mg/kg, ip) induced significant
differences in locomotor activity, rearing behavior, and conditioned place preference. The low
dose induced profound hyperlocomotion and rearing behavior compared with vehicle group,
while the medium and high dose significantly reduce the total distance travelled and number of
rears. Yusoff et. al. (2016) found the behavioral effects of MG at their largest dose (30 mg/kg) to
be similar to the effects of morphine as well as methamphetamine. Following the cessation of
MG treatment (30 mg/kg, ip) for 14 days, severe somatic withdrawal symptoms (e.g., paw
tremor, body tremor, wet‐dog shakes, ptosis, piloerection, teeth chattering and grooming)
developed after 12 hours and elevated levels of anxiety (significant decline in open arm time)
were evident after 24 and 48 hours (Yusoff et al., 2016). However, these somatic and anxiolytic
signs of withdrawal were reversed or disappeared after 72 hours, suggesting to the researchers
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that MG withdrawal effects could have a restricted period of 48 hours (Yusoff et al., 2016).
Similarly, Hazim et al. (2011) showed that acute MG induces locomotor activation at a low dose
but not at high doses in rodents. However, behavioral results surrounding the reinforcing effects
of MG are not all congruent. For example, MG has been shown to induce a conditioned place
preference for rats in doses of 10 mg/kg and 30 mg/kg, with the MG preference being similar in
magnitude to that of morphine and methamphetamine (Yusoff et al., 2016). On the contrary,
Hemby et al. (2018) found that none of their doses of MG (25, 50, 100 and 150 μg/inf) were selfadministered any differently than saline. Drug self-administration is a critical behavioral
paradigm for establishing/understanding abuse liability (O'Connor et al., 2011; Collins et al.,
1984). Furthermore, MG was not reliably self-administered when substituted for morphine, but
MG exposure at a low dose over a 2-week period significantly reduced morphine selfadministration up to 3 days following the last exposure (Hemby et al., 2018). Researchers from
this study also report their findings pertaining to MG are consistent with anecdotal reports
describing kratom use and a reduction in opiate intake (Hemby et al., 2018). Similarly, in rats
trained to self-administer methamphetamine, MG pretreatment (0.1 to 3.0 mg/kg) reduced
response rates maintained by heroin (Yue, Kopajtic, & Katz, 2018). Overall, more research is
needed on the rewarding value of MG.
Although less research has been conducted on 7-HMG, some researchers are suggesting
it may be more rewarding than MG, and that kratom distributors in the United States are altering
concentrations of 7-HMG for these desired effects (Lydecker et al., 2016). Notably, the current
lack of regulation, non-standardization, and possible contamination or adulteration of kratom
products poses perhaps the most significant risks to public health (Prozialeck et al., 2020). 7HMG has been shown to increase locomotor activity and produce CPP in rodents at 2 and 4
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mg/kg (Matsumoto et al., 2006; Matsumoto et al., 2008). Furthermore, self-administration of 7HMG was established in drug-naive rats and when substituted for morphine (Hemby et al.,
2018). Furthermore, 7-HMG self-administration exhibited an inverted ‘U’ dose–effect curve at 5
and 10 μg/inf, a pattern typically associated with drugs of abuse where high doses decrease
responding, potentially through aversion or motor impairment, and low to moderate doses
increase responding (Wilson, Hitomi, & Schuster 1971; Pickens 1978; Hemby et al. 2018).
While there is scarce research on 7-HMG and withdrawal symptoms, Hemby et al. (2018) found
that rats displayed an increased morphine intake after administrations of 7-HMG but no physical
signs of withdrawal (e.g., excretion of feces and urine, salivation, behavioral jumping, wet dog
shakes). Increased morphine intake following kratom exposure could be a compensatory
response to withdrawal from 7‐HMG or an indicator that 7-HMG has significant abuse potential
(Hemby et al., 2018). Although 7-HMG only constitutes 2% of the alkaloid content in kratom,
the concentration is sometimes higher in commercial products (Lydecker et al., 2016)
highlighting the need to further investigate this alkaloid.
The addictive properties of most drugs of abuse are driven by their ability to increase
activity of the mesolimbic dopamine pathway, which consists of dopamine cell bodies located in
the ventral tegmental area (VTA) that project to the limbic system, most notably the nucleus
accumbens (NAc) (Koob & Bloom, 1988; Wise, 2005). In freely moving rats, dopamine neurons
fire tonically at ~4hz and burst fire phasically at ~20hz (Hyland et al., 2002). Tonic firing is
suggested to occur when no behaviorally relevant stimuli are present and produces low
concentrations of extracellular dopamine (Goto et al., 2007). Conversely, phasic firing occurs in
relation to behaviorally significant external stimuli whose detection is crucial for learning
(Schultz et al., 1993). This mode of firing is thought to evoke a large enough extracellular
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concentration for the highlighting of salient stimuli (Middleton, 2000). To date, no studies have
examined the effects of kratom or the alkaloids MG and 7-HMG on phasic dopamine release,
and only one study related to tonic dopamine. Vijeepallum et al. (2019) found that a low dose of
the methanolic extract from the kratom leaf did not alter dopamine levels, as measured in
dissected brain regions with ELISA, but did attenuate ethanol-induced increases in dopamine
levels. Kratom has been shown to bind to dopamine D2 receptors (Boyer et al., 2008) while also
binding at low affinity to D1 receptors (Stolt et al., 2014). Repeated administration of MG has
been shown to decrease D2 and increase DAT sites in the mesencephalon, which houses the
VTA, but not in the NAc (Yusoff et al., 2014). Altogether these data suggest that kratom alters
dopamine functioning, but whether this dopaminergic effect results in the increased dopamine
activity levels associated with drugs of abuse is not clear.
Furthermore, the United States continues to struggle with the ongoing opioid epidemic,
even during the current pandemic. Historically, women have been prescribed opioids for the
treatment of acute and chronic pain in significantly greater numbers than men (Goetz, Becker,
and Mazure, 2021). The use of these prescription medications has been thought to be the primary
precursor for misuse and addiction to opioids for women (Goetz, Becker, and Mazure, 2021).
While the exact levels of women’s exposure and resultant consequences have been limited,
further research could be used to increase our understanding of the underlying biological and
psychosocial differences among men and women (Goetz, Becker, and Mazure, 2021). In animal
models, female rodents have been shown to exhibit more rapid acquisition and escalation of drug
taking, higher motivation for drugs of abuse, and more like to experience relapse-like behaviors
when compared to males (Becker, 2016). Becker and Chartoff (2019) make a crucial distinction
that there is evidence that the qualitative aspects of the addiction phases do not differ
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significantly between the males and females, but one sex might be more likely to exhibit a trait
when compared to the other which then results in population differences. However, heroin selfadministration has been found to be lower in males than females and are presumed to vary based
on variations in circulating ovarian hormones (Lacy, Strickland, Feinstein, Robinson, and Smith,
2016). Additionally, female rats have been shown to be more sensitive to the reinforcing and
locomotor stimulant effects of opioids and have greater opioid receptor density compared to
males (Craft, 2008). Further elucidation of this underlying neurobiological basis will be crucial
in expanding our understanding of the sex differences seen regarding opioids as well as kratom.

Current Study
The aim of the proposed study is to examine the effects of MG and 7-HMG on phasic
dopamine release in the NAc. Stimulation-evoked dopamine release will be quantified using in
vivo fixed potential amperometry in anesthetized mice before and after administration of MG, 7HMG, or vehicle. Fixed potential amperometry, also known as continuous amperometry, coupled
with carbon fiber recording microelectrodes is an established technique for real-time monitoring
of stimulation-evoked dopamine release (Dugast et al., 1994; Suaud-Chagny et al., 1995; Lester
et al., 2010; Holloway et al., 2018). Given the recurrence of dose-dependent effects in previous
studies with these alkaloids, we will administer three doses of each alkaloid representing low,
medium, and high doses. Administering MG or 7-HMG during phasic dopamine recordings will
allow for an assessment of the impact of these alkaloids on three measurements related to
dopamine transmission: dopamine release (magnitude of the dopamine response), dopamine
synaptic half-life (the time dopamine remains in the synapse, an indication of DAT functioning),
and dopamine autoreceptor sensitivity (an indication of presynaptic D2 functioning). We
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hypothesize that both alkaloids, at all doses, will increase NAc dopamine release to some degree,
with low doses producing greater dopaminergic effects compared to higher doses and 7-HMG
producing greater dopaminergic effects than MG. Given the underlying neurobiological factors
we also hypothesize that females will exhibit greater dopaminergic effects compared to males
across both alkaloids and at all doses. This study will improve our understanding of the
neurochemical mechanisms of kratom. Specifically, the proposed study will provide insight on
the impact of kratom on mesolimbic dopamine functioning and, consequentially, the abuse
liability of this drug.

Methods
Mice
Eighty-four C57BL/6J mice (42 male, 42 female) (Jackson Laboratories, Bar Harbor,
ME) will be housed five per cage in a temperature-controlled environment (21 ± 1 °C) on a 12-h
light/dark cycle (lights on at 0600). Food and water will be available ad libitum. All mice will be
12-20 weeks old at the time of experiments. All experiments were approved by the Institutional
Animal Care and Use Committee at the University of Memphis will be conducted in accordance
with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. In
order to maintain the principle of reduction related to scientific experiments on animals
(Kilkenny et al., 2010), efforts will be made to reduce the number of mice used. Efforts will also
made to minimize pain and discomfort.
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Surgery and Dopamine Recordings
Mice will be anesthetized with urethane (1.5 g/kg, i.p.) and placed in a stereotaxic frame
(David Kopf Instruments, Tujundga, CA) ensuring flat skull. Body temperature shall be
maintained at 36 ± 0.5 °C with a temperature-regulated heating pad (TC-1000; CWE, NY).
Following a longitudinal incision to expose the skull surface, three trephine holes (1 mm o.d.)
will be drilled. All stereotaxic coordinates have been confirmed in previous studies from our lab
(Lester et al., 2010; Holloway et al., 2018) and are presented in mm from bregma, midline, and
dura according to the mouse atlas of Paxinos and Franklin (2001). A stimulating electrode (SNE100; MicroProbes, Gaithersburg, MD) will be inserted into the left VTA (AP −3.3, ML +0.3, and
DV −4.0). A carbon fiber recording electrode with an active recording surface of 500 μm
(length) by 7 μm (o.d.) will be implanted in the NAc (AP + 1.5, ML +1.0, and DV −4.0) (Figure
1). A stainless-steel auxiliary and Ag/AgCl reference electrode combination will be positioned in
contact with contralateral cortical tissue 2.0 mm posterior to bregma. All amperometric
recordings will be made within a Faraday cage to increase signal to noise ratio. A fixed potential
(+0.8 V) will be applied to the recording electrode, and oxidation current monitored continuously
(10 K samples/s) with an electrometer (ED401 e-corder 401 and EA162 Picostat, eDAQ Inc.,
Colorado Springs, CO) filtered at 50 Hz (see Figure 1).
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Figure 1. Amperometric Set-up. In vivo fixed potential amperometry will used to quantify
nucleus accumbens (NAc) dopamine release evoked by stimulation of dopamine cell bodies
within the ventral tegmental area (VTA).

A series of cathodal monophasic current pulses, 20 pulses 0.5 ms in duration (800
μAmps) at 50 Hz every 30 s, was delivered to the stimulating electrode by an optical isolator and
programmable pulse generator (Iso-Flex/Master-8; AMPI, Jerusalem, Israel). Following a 10min baseline recording of stimulation-evoked dopamine release, mice received an i.p. injection
of either vehicle (20% Tween80 with saline), mitragynine (MG) (1, 15, or 30 mg/kg), or 7Hydroxymitragynine (7-HMG) (0.5, 1, or 2 mg/kg). See Table 1 for a breakdown of the
experimental groups. Baseline stimulation parameters and recordings were continued for 30-min
post injection whereupon dopamine autoreceptor sensitivity was assessed by applying a pair of
test stimuli (T1 and T2, each 10 pulses at 50 Hz separated by 10 s) to the MFB every 30 s. Five
sets of conditioning pulses (1, 5, 10, 20, and 40; 0.5 ms pulse duration at 15 Hz) were delivered
prior to T2 with 0.3 s between the end of the conditioning pulse train and T2 (Holloway et al.,
14

2018; Mittleman et al., 2011). Autoreceptor-mediated inhibition of evoked dopamine release was
expressed in terms of change in the amplitude of T2 with respect to T1 for each set of
conditioning pulses (i.e., higher autoreceptor sensitivity results in lower amplitude of T2 relative
to T1). Upon completion of the autoreceptor sensitivity test, stimulation parameters were reset to
20 pulses at 50 Hz every 30 s for 1 hour.

Table 1.
Number of Mice per Experimental Group
Sex

Drug

Dose

N

Male

MG

1 mg/kg

6

15 mg/kg

7

30 mg/kg

7

0.5 mg/kg

6

1 mg/kg

6

2 mg/kg

6

-

7

Total Males

45

1 mg/kg

6

15 mg/kg

6

30 mg/kg

6

0.5 mg/kg

6

1 mg/kg

5

2 mg/kg

5

-

6

Total Females

40

TOTAL MICE

85

7-HMG

Vehicle

Female

MG

7-HMG

Vehicle

Note. MG: mitrgynine, 7-HMG: 7-hydroxymitragynine, vehicle: 20% Tween80 with saline
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Following each experiment, an iron deposit was created to mark the stimulating electrode
site by sending direct anodic current (100 μA for 10 s) through the electrode. Mice were then
euthanized with intracardial injection of urethane. Brains were removed and stored in a 30%
sucrose/10% formalin solution with 0.1% potassium ferricyanide. Also, following each
experiment, carbon fiber electrodes calibrated in vitro using dopamine solutions (0.2–1.2 μM)
administered with a flow injection system (Michael and Wightman, 1999; Prater et al., 2018).
Thus, change in dopamine oxidation current (Amp) was converted to dopamine concentration
(M).
Drugs
Urethane and dopamine were obtained from Sigma-Aldrich Chemical (St Louis, MO).
Urethane was dissolved in distilled water, and dopamine was dissolved in phosphorate-buffered
saline (PBS pH 7.4). MG and 7-HMG were obtained via Dr. Christopher McCurdy at the
University of Florida and were dissolved in 20% Tween80 and saline (Hemby et al., 2018;
Vuppala et al., 2013).
Data Analysis
In order to quantify the recorded dopamine efflux, data points occurring at 0.25 sec preand 10 sec post-stimulation will be extracted at the time of interest. Starting 1 minute before the
drug injection to 1.5 hours post injection, stimulation-evoked responses will be analyzed every
10 minutes. At these time points, we will quantify dopamine release (the magnitude of the
response peak) and dopamine half-life (i.e. the time for 50% decrease from the maximum evoked
increase to the prestimulus baseline level). Mixed factorial ANOVAs will be used to determine
the effects of sex, drug, and dose (between-subjects factors) on dopamine release and half-life
over the 90-minute recording period (within-subjects factor). A mixed factorial ANOVA will
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also be used to determine the effects of sex, drug, and dose (between-subjects factors) on
autoreceptor functioning across the pre-pulse conditions (within-subjects factor). One-way
ANOVAs with Tukey’s HSD post-hoc tests will be used when appropriate to examine significant
group differences. For all analyses, alpha will be set at .05.

Results
Baseline Dopamine Release and Half-Life
Stimulation-evoked dopamine efflux was recorded before and after kratom alkaloid
administration (MG or 7-HMG). Baseline dopamine release (µM) and dopamine synaptic halflife (sec) were assessed in each mouse prior to the drug challenge. Neither baseline dopamine
release or half-life differed between males and females (release: [F(1,79) = .532, p = .468] ; halflife: [F(1,79) = 2.840, p = .096, ηp2= .035]. Furthermore, neither baseline dopamine release or
half-life differed between drug groups (vehicle, MG, or 7-HMG) (release: [F(2,79) = .763, p
= .469]; half-life: [F(2,79) = .040, p = .960]. These findings confirm that the randomly assigned
experimental groups contained no significant differences in dopamine functioning before drug
administration (see Figure 3A-C).
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Figure 3. Baseline dopamine release and half-life. (A) Example response. No significant
differences in (B) dopamine release or (C) half-life were observed between housing or drug
groups. Data is displayed as mean ± SEM.

Dopaminergic Response to MG
A mixed factorial ANOVA was used to determine the effects of sex and dose (0, 1, 15,
and 30 mg/kg MG) (between-subjects factors) on percent change in dopamine release throughout
the 90-minute recording period (in 10-minute intervals, within-subjects factor). Mauchly's test of
sphericity indicated that the assumption of sphericity had been violated, χ2(44) = 402.97, p
< .001, requiring the Greenhouse–Geisser correction be applied for evaluating main effects and
interactions. There was a significant main effect of time post injection on percent change in
dopamine release [F(2.71,116.69) = 193.12, p < .001, ηp2= .818]. There was a significant
interaction between time and sex on percent change in dopamine release [F(2.71, 116.69) = 2.83,
p = .047, ηp2= .062], but no significant interaction between time and dose [F(8.14,116.69) = .740,
p = .658]. A significant three-way time x sex x dose interaction was observed [F(8.14,116.69) =
2.25, p = .028, ηp2= .136]; thus follow-up analyses at each time point were employed. For each
sex, one-way ANOVAs at each time point revealed no significant release differences between
doses (p > .05) (see Figure 4A -B). While not significant at any specific time point, our results
indicate MG does have the ability to alter dopaminergic efflux over time depending on sex and
dose administered.
Regarding percent change in dopamine half-life following MG, Mauchly's test of
sphericity indicated that the assumption of sphericity had been violated, χ2(44) = 166.49, p
< .001, requiring the Greenhouse–Geisser correction be applied for evaluating main effects and
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interactions. There was a significant main effect of time post MG injection [F(3.62,155.62) =
2.53, p = .048, ηp2= .056], but no other interactions between time x sex [F(3.62,155.62) = 1.36, p
= .253], time x dose [F(10.86,155.62) = .850, p = .589], or time x sex x dose [F(10.86,155.62) =
.541, p = .871] significantly altered dopamine half-life.

Dopaminergic Response to 7-HMG
A mixed factorial ANOVA was used to determine the effects of sex and dose (0, 0.5, 1,
and 2 mg/kg 7-HMG) (between-subjects factors) on percent change of dopamine release
throughout the 90-minute recording period (in 10-minute intervals, within-subjects factor).
Mauchly's test of sphericity indicated that the assumption of sphericity had been violated, χ2(44)
= 449.98, p < .001, requiring the Greenhouse–Geisser correction be applied for evaluating main
effects and interactions. There was a significant main effect of time post injection on percent
change in dopamine release [F(2.39,93.34) = 117.49, p < .001, ηp2= .751], but no significant
interaction between time and sex [F(2.39,93.34) = .60 , p = .58], meaning there were no
significant differences between male or female groups at any given time point. There was a
significant interaction between time and dose on percent change in dopamine release
(significance is dependent on specific time points and doses of 7-HMG) [F(7.18,93.34) = 4.70, p
< .001, ηp2= .266], but no significant time x sex x dose interaction [F(7.18,93.34) = 1.24, p
= .288]. Given no effects of sex, follow-up analyses on the 7-HMG dose effect on dopamine
release were carried out with the male and female data combined. One-way ANOVAs at each
time point revealed significant dose effects on dopamine release at several time points (40 min: p
= .039; 60 min: p = .039; 70 min: p = .026; 80 min: p = .019; and 90 min: p = .026) (see Figure
3C). Tukey HSD post hoc tests further distinguished these group differences. Specifically, there
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were significant differences in release between the vehicle and high dose 7-HMG at 40 min and
between the low and high dose 7-HMG from 60-90 min (p < .05). (see Figure 4D-E).
Regarding percent change in dopamine half-life following 7-HMG, Mauchly's test of
sphericity indicated that the assumption of sphericity had been violated, χ2(44) = 176.64, p
< .001, requiring the Greenhouse–Geisser correction be applied for evaluating main effects and
interactions. There was no significant main effect of time [F(3.93,153.13) = 2.12, p = .083,
ηp2= .052], time x sex [F(3.93,153.13) = .659, p = .619], time x dose [F(11.78,153.13) = .690, p
= .756], or time x sex x dose [F(11.78,153.13) = 1.158, p = .319].

20

Figure 4. Dopamine release following drug challenge. (A) No significant differences in
dopamine release were observed for males or (B) females at any dose tested. (C) Significant
differences in release were observed between the vehicle and high dose 7-HMG at 40 min and
between the low and high dose 7-HMG from 60-90 min for both sexes. (D) Example of
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significant increase in stimulated dopamine release at 70 minutes. (E) Representative responses
from each dose of 7-HMG and VEH at 70 minutes.

Dopamine Autoreceptor Functioning
For the assessment of autoreceptor functioning a mixed factorial ANOVA was used to
determine the potential effects of sex and drug dose (between-subjects factors) on autoreceptor
functioning across varying pre-pulse settings (within-subjects factor). Autoreceptor-mediated
inhibition of evoked dopamine release was expressed in terms of the percentage change between
test stimulations (T1 and T2) for each set of conditioning pulses (or pre-pulses). With 0 pre-pulse
stimulation pairs near 100% dopamine release (no change between T1 and T2), percent release
of T2/T1 that is decreased from 100% indicates autoreceptor-mediated inhibition of dopamine
release (see Figure 5A-B). Thus, greater decreases in dopamine release (T2/T1) indicates
increased autoreceptor functioning. Assessments of autoreceptor functioning were conducted 20minutes post-injection across all groups.
Regarding autoreceptor functioning following MG administration, Mauchly's test of
sphericity indicated that the assumption of sphericity had been violated, χ2(20) = 177.19, p
< .001, requiring the Greenhouse–Geisser correction be applied for evaluating main effects and
interactions. There was a significant main effect of number of pre-pulses on percent change in
autoreceptor-mediated dopamine release [F(2.12,91.18) = 238.01, p < .001, ηp2= .847],
validating the test by confirming that the number of pre-pulses impacted dopamine release from
T1 to T2. There were not significant interactions between pre-pulses x sex [F(2.12,91.18) = .417,
p = .672] or pre-pulses x drug dose [F(6.36,91.18) = 1.94 p = .079, ηp2= .119]. However, there
was a significant 3-way interaction between pre-pulses x sex x drug dose [F(6.36,91) = 2.24, p
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= .043, ηp2= .135], indicating that MG altered autoreceptor functioning differently in males and
females. In males, follow-up tests indicated significant differences in autoreceptor-mediated
dopamine release between dose groups at 20 pre-pulses [F(3,23) = 3.76, p = .025, ηp2= .329] and
40 pre-pulses [F(3,23) = 3.27, p = .039, ηp2= .299](see Figure 5C), with the low dose MG mice
displaying significantly increased autoreceptor functioning relative to vehicle mice (p < .05). In
females, follow-up tests revealed no significant differences at any specific pre-pulse setting (p
> .05) (see Figure 5D).
Regarding autoreceptor functioning following 7-HMG, Mauchly's test of sphericity
indicated that the assumption of sphericity had been violated, χ2(20) = 144.81, p < .001,
requiring the Greenhouse–Geisser correction be applied for evaluating main effects and
interactions. There was a significant main effect of number of pre-pulses on autoreceptormediated dopamine release [F(2.31,90.09) = 261.35, p < .001, ηp2= .870], again indicating that
the number of pre-pulses impacted autoreceptor-mediated dopamine inhibition. There were not
significant interactions between pre-pulses and sex [F(2.31,90.09) = .933, p = .408], pre-pulses
and drug dose [F(6.9,90.09) = 1.32 p = .252], or pre-pulses x sex x drug dose [F(6.93,90.09)
= .987, p = .446]. No follow-up analyses were conducted as 7-HMG did not alter autoreceptormediated dopamine release (see Figure 4E).
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Figure 5. Autoreceptor-mediated inhibition of dopamine release. (A) Example amperometric
recording of autoreceptor test stimulations (T1,T2) separated by 1 pre-pulse (pp) and (B) 40 prepulses. Greater decreases in dopamine release (% of T2/T1) indicates increased autoreceptor
functioning. (C) Low dose MG significantly increased autoreceptor functioning (greater decrease
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in dopamine release) in males relative to vehicle mice at 20 and 40 pre-pulses. (D) In females, no
significant differences at any specific pre-pulse setting were observed. (E) 7-HMG did not alter
autoreceptor-mediated dopamine release at any dose tested.

Discussion
The aim of the proposed study was to examine the effects of kratom’s two primary
alkaloids, MG and 7-HMG, on phasic dopamine release in the NAc, an area often targeted by
drugs of abuse. In vivo fixed potential amperometry was used to quantify VTA stimulationevoked dopamine release in anesthetized mice. During dopamine recordings, mice received an
i.p. injection of either MG (1, 15, or 30 mg/kg i.p.), 7-HMG (0.5, 1, or 2 mg/kg i.p.), or vehicle,
and dopamine recordings continued for 90 minutes. We examined the effects of these drugs on
dopamine release concentrations, the synaptic half-life of dopamine, and dopamine autoreceptor
functioning. Both MG and 7-HMG dose-dependently altered aspects of stimulation-evoked
dopamine release, but in different ways, suggesting different mechanisms at play between the
two kratom alkaloids.

Effects of MG on phasic dopamine release
The effects of MG on stimulation-evoked dopamine release were both sex- and dosedependent. We observed a significant time x sex x MG dose interaction, indicating that the
amount of dopamine released across the 90 min recording period was altered differently in males
and females based on the dose of MG administered. As shown in Figure 3A, it appears that for
males the low MG dose (1 mg/kg) lead to a response pattern separate from the other doses, in the
direction of increased dopamine release. However, follow-up tests did not show significant
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differences in release at any of the specific time points in either males or females. More research
is needed to determine what this may mean. Perhaps examining more dosages in the lower dose
range (such as 0.5 or 2 mg/kg) would shed light on these findings. While no others have
examined the effect of MG on dopamine release, our findings coincide to some degree with what
is currently available in pre-clinical behavioral paradigms and clinical reports. In animal models
utilizing males, acute MG administration at low dose (1 mg/kg i.p.) has been found to induce
significant locomotor activity and rearing behaviors compared to the vehicle group (Yusoff et.
al., 2016; Hazim et al., 2011). Similarly, in regions such as Southeast Asia kratom leaves are
historically and commonly chewed predominantly by men throughout the workday who
reportedly utilize its complex stimulant effects in the morning to combat fatigue and improve
work productivity (Suwanlert, 1975; Ahmad et al. 2012). All of these findings suggest that the
low MG doses have neural actions similar to stimulants. Regarding the lack of response to MG
in females, females have been shown to have a smaller accumbal response to drug stimulants
compared to males, but then exhibit more rapid acquisition and escalation of drug taking
compared to males (see Becker, 2016). Thus future studies examining the effects of repeated MG
administration on dopamine release are needed.
Extracellular dopamine concentrations are mediated by a large number of neural
mechanisms, two of which are the functioning of DAT and dopamine autoreceptors. As
measured in the current study, the synaptic half-life of dopamine conveys the amount of time
required to clear dopamine from the synapse. Therefore, the synaptic half-life of dopamine is an
indication of DAT functioning, with an increased half-life indicating decreased DAT functioning
(Ford, 2014). MG administration did not alter the dopamine half-life over the 90 min recording
period, indicating that MG did not act on DAT. Many psychostimulants (such as cocaine and
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amphetamine) inhibit DAT and dramatically increase the synaptic half-life of evoked dopamine
(Lester et al., 2010; Holloway et al., 2018), but MG does not appear to share this mechanism
with other psychostimulants. Yusoff et al. (2014) found that repeated administration of MG did
not alter the number of DAT sites in the NAc but did increase the number of DAT sites in the
mesencephalon (which houses the VTA). Thus, measurements of somatodendritic dopamine
release in the VTA following MG may provide more information about the effects of MG on
DAT in this pathway.
The high temporal resolution of fixed potential amperometry allows for the assessment of
autoreceptor-mediated inhibition of dopamine release (Holloway et al., 2018; Mittleman et al.,
2011). We observed a significant interaction between the number of pre-pulses applied, sex, and
MG dose, indicating that the dose of MG administered altered the way male and female mice
responded to the autoreceptor test. Specifically, the low dose of MG significantly increased
dopamine autoreceptor functioning in males, leading to decreased dopamine release during these
assessments. No significant effects of MG on autoreceptor functioning were observed in females.
Previous research has established that dopamine autoreceptor sensitivity can be an indication of
presynaptic D2 functioning (Ford, 2014) and mitragynine has been shown to have partial affinity
for D2 dopamine receptors (Boyer et al., 2008). The present findings suggest that MG acts as a
D2 agonist at low doses in males. Similarly, Stolt et al. (2014) found that kratom extract (at 2
mg/kg) decreased locomotor activity and that this effect was counteracted by a low dose of
apomorphine, leading the authors to conclude that this dopaminergic effect of kratom was
presynaptic (functionally dopamine antagonistic). Furthermore, the behavioral effects of MG
have been compared to those of antipsychotics, which are typically dopamine antagonists
(Johnson et al., 2020; Vijeepallam et al., 2016). Most antipsychotics are D2 receptor antagonists
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(at post-synaptic sites), which has led some researchers to suggest that MG may antagonize D2
receptors (Johnson et al., 2020; Vijeepallam et al., 2016). Some antipsychotics have a dual mode
of action on D2 receptors, acting on presynaptic sites at low doses and postsynaptic sites at high
doses (Müller-Spahn, 2002). It is possible that MG has a similar dose-dependent effect on D2
sites (Stolt et al., 2014). The technique used in the present study would not detect actions at postsynaptic D2 receptor sites; thus, more research is needed to elucidate these dose- and sexdependent effects of MG on D2 functioning.

Effects of 7-HMG on phasic dopamine release
The effects of 7-HMG on the measured aspects of phasic dopamine release were different
than that of MG, suggesting the use of alternate neural mechanisms. Unlike MG, the
dopaminergic effects of 7-HMG were not sex-dependent; however, similar to MG, the
dopaminergic effects of 7-HMG were dose-dependent. We observed a significant time x 7-HMG
dose interaction on dopamine release, indicating that the amount of dopamine released across the
90 min recording period was altered by 7-HMG. Specifically, 7-HMG at the lowest dose tested
(0.5 mg/kg) significantly increased dopamine release from 60-90 minutes post injection,
although not to the extent of known drugs of abuse. Interestingly, the highest dose of 7-HMG
decreased dopamine release and whether this decrease is comparable to other therapeutic drugs
remains to be seen. Although not conclusive, this notable dose-dependent release is currently
leading researchers to compare kratom’s D2 binding effects to medications that treat the positive
symptoms of psychosis such as haloperidol and chlorpromazine (Vijeepallam, Pandy,
Kunasegaran, Murugan, and Naidu, 2016). Additionally, even though we did not see any
significant differences regarding 7-HMG and half-life, emerging research has also suggested that
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7-HMG may have a limited capability to cross the blood-brain barrier and longer elimination
half-life (2.4x) compared to MG (Maxwell et al., 2021).
Albeit these results show MG and 7-HMG do seem to have the potential to alter
dopamine release in a dose dependent manner. There is also emerging evidence that indicates
kratom’s alkaloids activate α-2 adrenergic postsynaptic receptors which are present in
modulatory pain pathways (Eastlack, 2020), without the recruitment of the beta-arrestin 2
pathway which is thought to be responsible for the undesirable effects seen in traditional opioids
such as respiratory depression, constipation, and dependence (Johnson et al., 2020). Furthermore,
when compared to the risk of evoked respiratory depression and overdose rates associated with
high doses of traditional prescription opioids (mu-opioid receptor agonists), additional stringent
investigation into kratom’s unique pharmacology could offer drug development researchers a
compound with comparable analgesic, anxiolytic, or antidepressant effects with a better safety
profile (ex: exclusively oral route of administration), therapeutic index, or lower abuse liability.
Some researchers even estimate the risk of overdose death is >1000 times greater for opioids
than for kratom (Henningfield, 2019). Particularly when considering preliminary data from the
CDC (2021) indicating drug overdose deaths in the United States rose 29.4% in 2020 to 93,331
(69,710 involving opioids), the investigation of novel treatments has become critical in
addressing our ever-growing crisis. However, while our results can provide valuable insight
regarding kratom’s potential abuse liability and/or therapeutic utility (from previously mentioned
studies), additional investigations will inevitably be paramount in furthering our understanding
of this largely obscure plant and its novel alkaloids.
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Indications of abuse liability
Our findings suggested the increases in dopamine release were considerably less than those
normally observed in stimulants with a high abuse liability. More precisely in males, our results
indicated low dose MG (1 mg/kg) increased dopamine release over time (+23% from vehicle for
70-90mins), but also increased dopamine autoreceptor functioning (+50% from vehicle).
Comparatively, other studies from our lab have shown increases (329% ± 45) (322.53% ± 60.48)
in intra-NAC dopamine release from psychostimulant administration (Holloway et al., 2018;
Freels et al., 2020). Previous research has also shown low dose MG (1mg/kg i.p.) induced
profound hyperlocomotion and rearing behavior compared with vehicle group (Yusoff et. al.,
2016; Hazim et al., 2011). Pertaining to the significance of our findings regarding increased
dopamine autoreceptor functioning (decreased release) at low dose MG (1 mg/kg), prior findings
in rats have revealed MG exposure at a low dose (25 μg/inf) significantly reduced morphine selfadministration up to 3 days following the last exposure (Hemby et al., 2018) and MG
pretreatment (0.1 to 3.0 mg/kg) reduced response rates maintained by heroin (Yue, Kopajtic, &
Katz, 2018). Concerning the significant differences seen across male and female mice in
dopamine release from 60-90 minutes, the low dose of 7-HMG (0.5 mg/kg) increased dopamine
release (+18% from vehicle) whereas the high dose (2 mg/kg) decreased dopamine release (-22%
from vehicle). However, similarly to MG, our observed increase in dopamine release at low dose
7-HMG (+18%) was considerably less than those seen in the NAc following high dose of
methadone (10 mg/kg) (+300%) or fentanyl infusions of 0.5 nmol (+132%), 2.5 nmol (+216%),
and 5.0 nmol (+682%) (Di Chiara and Imperato, 1988; Yoshida et al., 1999). Lastly, despite the
fact an increase in dopamine release is typically associated with a higher risk of abuse and
greater likelihood of negative outcomes, the reduction of dopamine release at the highest 7-HMG
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dose (2 mg/kg) tested is not without risk. The reduction in dopamine following high dose 7HMG administration could potentially lead to a diminished interest in pleasurable activities or a
reduction in the ability to experience pleasure itself, otherwise known as anhedonia (APA, 2013).
Along with the potential loss of pleasure, anhedonia is oftentimes synonymous with depression
and is associated with sedation, reduced motivation, and a reduced willingness to expend
cognitive and physical effort for rewards (Horne, Topp, and Quigley, 2021). Furthermore, there
is emerging evidence that opioid use disorder (OUD) has the greatest odds of being accompanied
by anhedonia relative to other substance use disorders (SUD), although anhedonia is more likely
to be seen in mood disorders and post-traumatic stress disorder (PTSD) (Stull et al., 2021).
However, people with a history of PTSD, mood disorder, or OUD may be populations that are
particularly vulnerable to anhedonia when seeking treatment for substance use disorders (Stull et
al., 2021).

Limitations
The quantity and diversity of the alkaloids found in kratom, and its associated products,
represent one of the most unique, pharmacologically complex substances that we are currently
aware of. Kratom’s relatively unknown status and ability to produce opiate-like and stimulantlike effects in a dose-dependent manner along with suspected mental health effects not only
makes it an excellent candidate for drug development programs or potentially for treatment
facilities, but also for labs investigating its abuse liability, mechanisms of action, or safety. While
MG and 7-HMG are thought to represent the 2 major psychoactive alkaloids found in kratom,
there are more than 3 dozen alkaloids found in kratom (Johnson et al., 2020), most of which
there is scant research available. Unfortunately, one of the limitations within the realm of
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preclinical evidence is that much of the research we currently have has been conducted using
extracted MG and/or 7-HMG (not commercial products) via routes of administration that are not
typically seen in human populations. Additionally, future studies could explore variations in
housing, age, enrichment, pretreatment, or drug exposure time (acute vs chronic) prior to
surgeries and dopamine recordings. Further pre-clinical investigations could also track the estrus
cycles of their female rodents to better illuminate any significant sex differences seen. It is also
worth considering that in our study we are measuring a programable stimulated dopamine release
on fixed schedules that may not be entirely consistent with the firing rates that drive reward
outside of a laboratory setting or in combination with other substances or drugs of abuse. Lastly,
and perhaps most importantly, further investigation into the combinations and variable
concentrations of these alkaloids will be paramount in the exploration of kratom’s
neuropharmacological mechanisms and effects.

Conclusions
The present study aimed to determine the effect of the 2 main alkaloids in kratom (MG
and 7-HMG) on reward-related neurotransmission using in vivo fixed potential amperometry to
quantify stimulation-evoked dopamine release in the NAc of anesthetized male and female mice.
In males, dopamine release over the recording period was alter based on MG dose, with the
lowest dose (1 mg/kg) appearing to increase dopamine release. The low dose of MG also
increased dopamine autoreceptor functioning in males. Neither of these MG responses were
observed in females. No sex effects were observed following 7-HMG. Dopamine release over
the recording period was altered by the dose of 7-HMG, with dopamine release being
significantly greater following the low dose compared to the high dose (with the control mice
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responding in the middle). By providing insight on some of the neurochemical effect of
components within kratom, a relatively new and readily available opioid, these results will join a
growing body of research that will inevitably help provide vital information surrounding one of
the United States’ largest public health issues, the opioid crisis. The understanding of this greater
context in which kratom is nestled and having the necessary information regarding its abuse
potential, mortality risk associated with the combination of other substances/medications, or
therapeutic utility is imperative in the current epidemic of opioid abuse. Our results show that
kratom does have the potential to dose-dependently alter dopamine release, but not to the extent
of traditional drugs of abuse (such as cocaine or morphine). Historically, kratom has exclusively
been associated with opioids or stimulants, but recently its alkaloids have also begun to be
considered for their unique targeting of mu opioid, serotonin, and dopamine receptors as
innovative treatments for pain relief, opioid withdrawal, and various mental health disorders.
Ultimately, this study has increased our understanding of kratom’s 2 major alkaloids and their
abilities to alter dopamine release, but further investigation surrounding the neural mechanisms
of kratom’s alkaloids and their interactions will provide crucial and urgent insight into their
therapeutic uses or potential abuse liability.
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